EA201991667A1 - Экстренное лечение постоперационной тошноты и рвоты - Google Patents
Экстренное лечение постоперационной тошноты и рвотыInfo
- Publication number
- EA201991667A1 EA201991667A1 EA201991667A EA201991667A EA201991667A1 EA 201991667 A1 EA201991667 A1 EA 201991667A1 EA 201991667 A EA201991667 A EA 201991667A EA 201991667 A EA201991667 A EA 201991667A EA 201991667 A1 EA201991667 A1 EA 201991667A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- vomiting
- postoperative nausea
- emergency treatment
- nausea
- amisulpride
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1702250.0A GB201702250D0 (en) | 2017-02-10 | 2017-02-10 | Method |
| PCT/GB2018/050374 WO2018146490A1 (en) | 2017-02-10 | 2018-02-09 | Rescue treatment of post operative nausea and vomiting |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201991667A1 true EA201991667A1 (ru) | 2020-02-11 |
Family
ID=58462198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201991667A EA201991667A1 (ru) | 2017-02-10 | 2018-02-09 | Экстренное лечение постоперационной тошноты и рвоты |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US11357753B2 (https=) |
| EP (1) | EP3579831A1 (https=) |
| JP (2) | JP7333269B2 (https=) |
| KR (2) | KR20240001288A (https=) |
| CN (1) | CN110603036A (https=) |
| AU (2) | AU2018218310B2 (https=) |
| BR (1) | BR112019016565A2 (https=) |
| EA (1) | EA201991667A1 (https=) |
| GB (1) | GB201702250D0 (https=) |
| IL (2) | IL268591B2 (https=) |
| MX (1) | MX388736B (https=) |
| NZ (1) | NZ796242A (https=) |
| WO (1) | WO2018146490A1 (https=) |
| ZA (1) | ZA201905212B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201702250D0 (en) * | 2017-02-10 | 2017-03-29 | Acacia Pharma Ltd | Method |
| IT201900013524A1 (it) | 2019-07-31 | 2021-01-31 | Laboratori Baldacci Spa | Nuove formulazioni di amisulpride |
| CN115867271A (zh) * | 2020-07-06 | 2023-03-28 | 阿卡西亚制药有限公司 | 术后恶心和呕吐的疗法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1004020A (en) | 1964-04-24 | 1965-09-08 | Standard Telephones Cables Ltd | Improvements in or relating to the mounting of electrical components |
| FR2415099A1 (fr) | 1978-01-20 | 1979-08-17 | Ile De France | Nouveaux derives de 4-amino-5-alkylsulfonyl ortho-anisamides, leurs procedes de preparation et leur application comme psychotropes |
| GB9305593D0 (en) | 1993-03-18 | 1993-05-05 | Smithkline Beecham Plc | Pharmaceuticals |
| US6169094B1 (en) | 1998-07-14 | 2001-01-02 | Sanofi-Synthelabo | Compositions of (S) (-)-amisulpride |
| DE10163421A1 (de) | 2001-12-21 | 2003-07-31 | Gruenenthal Gmbh | Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum |
| TWI355936B (en) | 2003-02-18 | 2012-01-11 | Helsinn Healthcare Sa | Uses of palonosetron hydrochloride |
| DE102005013726A1 (de) | 2005-03-22 | 2006-09-28 | Grünenthal GmbH | Transdermale therapeutische Systeme mit verbesserter Verträglichkeit |
| GB0506800D0 (en) | 2005-04-04 | 2005-05-11 | Merck Sharp & Dohme | New uses |
| WO2007067714A2 (en) | 2005-12-08 | 2007-06-14 | The Mclean Hospital Corporation | Treatment of sequelae of psychiatric disorders |
| CN103211779B (zh) | 2006-01-27 | 2016-03-16 | 阿代尔制药股份有限公司 | 包含弱碱性选择性5-羟色胺5-ht3阻断剂和有机酸的药物递送系统 |
| EP1988883A1 (fr) | 2006-02-17 | 2008-11-12 | Trimaran Limited | Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement global des addictions |
| US7825156B2 (en) | 2007-02-02 | 2010-11-02 | Copharms | Method of treating bipolar depression with a benzamide derivative |
| ES2620672T3 (es) | 2008-01-09 | 2017-06-29 | Charleston Laboratories, Inc. | Comprimidos de doble capa que comprenden oxicodona y prometazina |
| US8138169B2 (en) | 2008-04-11 | 2012-03-20 | Comgenrx, Inc. | Combination therapy for bipolar disorder |
| US20110003005A1 (en) | 2009-07-06 | 2011-01-06 | Gopi Venkatesh | Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions |
| PT2722045T (pt) | 2009-11-18 | 2016-10-18 | Helsinn Healthcare Sa | Composições para o tratamento de náuseas e vómitos mediadas centralmente |
| GB201004020D0 (en) | 2010-03-11 | 2010-04-21 | Acacia Pharma Ltd | New therapeutic use |
| US8691836B2 (en) | 2010-06-18 | 2014-04-08 | Altos Therapeutics, LLC | D2 antagonists, methods of synthesis and methods of use |
| WO2015054429A1 (en) | 2013-10-08 | 2015-04-16 | Innopharma, Inc | Aprepitant oral liquid formulations |
| GB201506116D0 (en) | 2015-04-10 | 2015-05-27 | Acacia Pharma Ltd | Kit and combination therapy for nausea and vomiting |
| GB201618425D0 (en) | 2016-11-01 | 2016-12-14 | Acacia Pharma Ltd | method |
| GB201702250D0 (en) | 2017-02-10 | 2017-03-29 | Acacia Pharma Ltd | Method |
-
2017
- 2017-02-10 GB GBGB1702250.0A patent/GB201702250D0/en not_active Ceased
-
2018
- 2018-02-09 AU AU2018218310A patent/AU2018218310B2/en active Active
- 2018-02-09 JP JP2019543311A patent/JP7333269B2/ja active Active
- 2018-02-09 EP EP18705483.8A patent/EP3579831A1/en active Pending
- 2018-02-09 KR KR1020237044292A patent/KR20240001288A/ko active Pending
- 2018-02-09 CN CN201880011444.1A patent/CN110603036A/zh active Pending
- 2018-02-09 KR KR1020197023506A patent/KR20190111993A/ko not_active Ceased
- 2018-02-09 IL IL268591A patent/IL268591B2/en unknown
- 2018-02-09 IL IL298486A patent/IL298486B2/en unknown
- 2018-02-09 EA EA201991667A patent/EA201991667A1/ru unknown
- 2018-02-09 MX MX2019009507A patent/MX388736B/es unknown
- 2018-02-09 BR BR112019016565-7A patent/BR112019016565A2/pt not_active Application Discontinuation
- 2018-02-09 NZ NZ796242A patent/NZ796242A/en unknown
- 2018-02-09 WO PCT/GB2018/050374 patent/WO2018146490A1/en not_active Ceased
- 2018-02-09 US US16/485,008 patent/US11357753B2/en active Active
-
2019
- 2019-08-07 ZA ZA2019/05212A patent/ZA201905212B/en unknown
-
2022
- 2022-05-17 US US17/746,032 patent/US12005042B2/en active Active
- 2022-12-08 JP JP2022196161A patent/JP7526244B2/ja active Active
-
2024
- 2024-05-02 US US18/653,318 patent/US12329740B2/en active Active
- 2024-05-13 AU AU2024203155A patent/AU2024203155B2/en active Active
-
2025
- 2025-05-19 US US19/211,545 patent/US20250367211A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12005042B2 (en) | 2024-06-11 |
| IL298486A (en) | 2023-01-01 |
| JP7526244B2 (ja) | 2024-07-31 |
| KR20240001288A (ko) | 2024-01-03 |
| IL268591B (en) | 2022-12-01 |
| US11357753B2 (en) | 2022-06-14 |
| EP3579831A1 (en) | 2019-12-18 |
| US20230100786A1 (en) | 2023-03-30 |
| JP7333269B2 (ja) | 2023-08-24 |
| US20200038369A1 (en) | 2020-02-06 |
| AU2018218310A1 (en) | 2019-08-22 |
| CA3052535A1 (en) | 2018-08-16 |
| MX388736B (es) | 2025-03-20 |
| US20240285579A1 (en) | 2024-08-29 |
| ZA201905212B (en) | 2023-12-20 |
| IL268591B2 (en) | 2023-04-01 |
| NZ796242A (en) | 2026-01-30 |
| IL298486B2 (en) | 2024-09-01 |
| US20250367211A1 (en) | 2025-12-04 |
| JP2023027213A (ja) | 2023-03-01 |
| AU2024203155B2 (en) | 2025-03-13 |
| WO2018146490A1 (en) | 2018-08-16 |
| CN110603036A (zh) | 2019-12-20 |
| GB201702250D0 (en) | 2017-03-29 |
| AU2018218310B2 (en) | 2024-02-15 |
| KR20190111993A (ko) | 2019-10-02 |
| AU2024203155A1 (en) | 2024-05-30 |
| IL268591A (en) | 2019-09-26 |
| NZ756051A (en) | 2024-04-26 |
| IL298486B1 (en) | 2024-05-01 |
| US12329740B2 (en) | 2025-06-17 |
| BR112019016565A2 (pt) | 2020-03-31 |
| JP2020506209A (ja) | 2020-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201290833A1 (ru) | Применение амисульприда в качестве противорвотного средства | |
| MX2021002321A (es) | Nuevos metodos. | |
| IL268960A (en) | 7,6,5,4-Tetrahydroisoxazazole (4,5-c) Pyridin-3-ol (thip) for use in the treatment of broken x syndrome | |
| CR20210368A (es) | Combinación de dextrometorfano y bupropión para el tratamiento de depresión | |
| WO2015054619A3 (en) | Use of a pcsk9 inhibitor to treat hyperlipidemia | |
| MX384403B (es) | Terapia de combinación para el tratamiento del cáncer. | |
| WO2015123423A3 (en) | Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy | |
| MX390627B (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| EP4353317A3 (en) | Ret inhibitor for use in treating cancer having a ret alteration | |
| MX2019015212A (es) | Compuestos para el tratamiento del sarcoma. | |
| WO2017121646A8 (en) | 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives | |
| EA201991667A1 (ru) | Экстренное лечение постоперационной тошноты и рвоты | |
| EA201501164A1 (ru) | Твердая фармацевтическая лекарственная форма | |
| EP4631569A3 (en) | Alginate film comprising a triptan | |
| AU2017394032A8 (en) | Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome | |
| EA201990995A1 (ru) | Терапия постоперационной рвоты амисульпридом | |
| EA202190317A1 (ru) | Лекарственный препарат для наружного применения | |
| EA202091062A1 (ru) | Карбоксилхитозан | |
| PH12020500606A1 (en) | Use of functionalized calcium carbonate as active ingredient | |
| UA117833U (uk) | Спосіб лікування синдрому післяопераційної нудоти та блювання у пацієнтів після лапароскопічної холецистектомії | |
| EA202090803A1 (ru) | Фармацевтическая композиция адапалена и миноциклина для наружного применения | |
| UA126148U (uk) | Спосіб лікування періімплантного мукозиту | |
| MX2021004997A (es) | Tratamiento y prevencion de la eyaculacion precoz (ep). | |
| CY1124264T1 (el) | Απο toy στοματος θεραπευτικος παραγοντας του θυρεοειδους | |
| RU2013127881A (ru) | Применение фармацевтической композиции на основе соли четвертичного фосфония и замещенного динитробензофуроксана для лечения пироплазмоза у собак и способ лечения |